AIM
ADAP

Acrospire Investment Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Acrospire Investment Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-400
Closed -$2K – 2181
2016
Q4 		$2K Buy
+400
New +$1.92K ﹤0.01% 2119

Other funds holding ADAP

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Acrospire Investment Management's ADAP Position: Q1 2017 in Review

Acrospire Investment Management sold out of Adaptimmune Therapeutics (ADAP) in Q1 2017, closing a stake of 400 shares — an estimated $2K sold.

Acrospire Investment Management first reported a position in ADAP in Q4 2016 and held it in 1 quarter. The position peaked at $2K in Q4 2016. 49 funds tracked by Wall St. Rank hold ADAP as of Q1 2017.

  • Acrospire Investment Management reported no remaining Adaptimmune Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 400 Adaptimmune Therapeutics shares in Q1 2017, an estimated $2K.
  • Acrospire Investment Management first reported a position in Adaptimmune Therapeutics in Q4 2016 and held it in 1 quarter.
  • Acrospire Investment Management's Adaptimmune Therapeutics position peaked at $2K in Q4 2016.
  • 49 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.